Abstract 189P
Background
Tertiary lymphoid structures (TLSs) are lymphocyte aggregates that correlate with better prognosis in most cancers. TLSs possess anti-tumor potentials but their compositions and functions vary across cancer types and stages, so our understanding of TLS remains largely descriptive. Current studies are limited to fixed pathological samples for immunohistochemistry or spatial transcriptomics, yielding restricted mRNA content in rare cell types. To study the anti-tumor role of TLS, we choose prostate cancer, cause of one of the highest cancer-related deaths in U.S, as our disease model. Castration-resistant prostate cancer (CRPC) is a devastating disease state with high mortality and limited treatment options, including immune checkpoint therapy (ICT). Due to the positive correlation between TLS and ICT response, we want to promote the anti-tumor potentials of TLS in CRPC.
Methods
We aim to develop a region-specific in situ labeling methodology to capture live TLS cells in CRPC mice for characterizations. Since loss of PTEN is a common mutation in prostate cancer, we employed PB-Cre+;Ptenloxp/loxp mice to elucidate TLS composition and function in CRPC. Through photocatalytic labeling in tissue sections, we covalently tagged biotin to live TLS cells, followed by biotin+ TLS isolation for single-cell RNA sequencing (scRNA-seq) analysis.
Results
Our region-specific labeling method is validated in cell lines and tissue sections, including germinal center (GC) enrichment. Our study identified key clusters within CRPC TLS, including CD8+T, follicular helper T (Tfh), GC B, Mki67+ T/B cells and Naaa+ dendritic cells (DCs), among others. TLS also enriched for certain clones in TCR/BCR repertoires.
Conclusions
Through photocatalytic covalent labeling with biotin, we achieved image-guided labeling of live TLS cells for scRNA-seq and identified TLS-enriched cells with potential functions in antigen presentation, cytotoxicity and antibody secretion. We anticipate detecting changes in TLS signatures and functions following PI3K drug treatment, enabling a comprehensive analysis of TLS. Moreover, we plan to refine our methodology to expand the scope of application in other crucial biomedical research areas.
Legal entity responsible for the study
Peking University.
Funding
Peking University; Shenzhen Bay Laboratory.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract